Using a different chemotherapy drug to prevent the return of breast cancer is just as effective as the current standard approach and crucially ... but the results showed that it wasn’t. This trial was ...

Post hoc data from TAILORx show that adding an anthracycline to taxane-based chemotherapy benefits patients with HR-positive ...

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally ...